- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.06. | SenzaGen AB: SenzaGen's subsidiary receives two orders within non-animal testing with a total value of SEK 2.4 million | 172 | GlobeNewswire (Europe) | SenzaGen's subsidiary VitroScreen has received two orders from existing customers for non-animal testing. The total order value amounts to SEK 2.4 million, with the majority of revenues expected to... ► Artikel lesen | |
| 12.05. | SenzaGen AB: Report from AGM of SenzaGen AB on 12 May 2026 | 270 | GlobeNewswire (Europe) | The Annual General Meeting (AGM) of SenzaGen held on today's date, 12 May 2026 in Lund, resolved to pass all proposals presented by the board and shareholders.
Adoption of income statement and balance... ► Artikel lesen | |
| 12.05. | SenzaGen AB: SenzaGen's interim report January-March 2026 | 10% sales growth alongside increased attention to non-animal methods | 257 | GlobeNewswire (Europe) | Message from the CEO"We started the year with 10 percent growth despite negative foreign exchange effects and the impact of a subsidiary undergoing a transition. At the same time, we maintained our... ► Artikel lesen | |
| 15.04. | SenzaGen AB: SenzaGen's subsidiary receives strategically important order | 276 | GlobeNewswire (Europe) | SenzaGens's subsidiary VitroScreen has received an order from an existing customer for non-animal efficacy testing. The order includes studies using the proprietary platform VitroScreenORA® and is carried... ► Artikel lesen | |
| 31.03. | XFRA NEW INSTRUMENTS AVAILABLE ON 31.03.2026 | 623 | Xetra Newsboard | The following instruments on XETRA do have their first trading 31.03.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 31.03.2026
Aktien
1 SE0009697204 Boho Group AB
2 SE0008321608... ► Artikel lesen | |
| SENZAGEN Aktie jetzt für 0€ handeln | |||||
| 30.03. | SenzaGen AB: SenzaGen wins new global cosmetics group as customer | 243 | GlobeNewswire (Europe) | SenzaGen has received a first order from a leading global group in the cosmetics sector, one of the company's prioritized industry segments. The customer will begin by testing with GARD®skin Dose-Response... ► Artikel lesen | |
| 13.02. | SenzaGen AB: SenzaGen carries out a directed issue of approximately SEK 17.5 million to the institutional investor Eiffel Investment Group | 235 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE ANNOUNCED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND... ► Artikel lesen | |
| 13.02. | SenzaGen AB: SenzaGen's Year-End Report 2025 | SenzaGen closes the year with continued strong GARD sales | 277 | GlobeNewswire (Europe) | Message from the CEO
"As previously stated in the half-year report, 2025 performance was stronger in the second half of the year. GARD® continued to strengthen its market position with positive sales... ► Artikel lesen | |
| 16.12.25 | SenzaGen AB: SenzaGen further strengthens US market position with 1.5 MSEK order from global chemical industry leader | 219 | GlobeNewswire (Europe) | SenzaGen continues to solidify its role as an important partner for customers with high safety testing requirements, securing an assignment worth approximately 1.5 MSEK from a leading American chemical... ► Artikel lesen | |
| 20.11.25 | SenzaGen AB: SenzaGen opens expanded laboratory facilities to strengthen capacity in line with 2030 growth plan | 233 | GlobeNewswire (Europe) | To support its recently announced growth strategy through 2030, SenzaGen has opened expanded office and laboratory facilities in Lund. This investment strengthens the company's ability to meet the growing... ► Artikel lesen | |
| 18.11.25 | SenzaGen AB: UK signals shift to non-animal testing - new opportunities for SenzaGen | 235 | GlobeNewswire (Europe) | The UK government has recently unveiled a national strategy to accelerate the phase-out of animal testing in research and product development. The plan includes clear timelines and governance to ensure... ► Artikel lesen | |
| 05.11.25 | SenzaGen AB: SenzaGen's interim report January-September 2025 | Growth and break-even in Q3 | 213 | GlobeNewswire (Europe) | Message from the CEO"We delivered a strong third quarter in line with our expectations, with higher sales and significantly improved EBITDA, both sequentially and year on year, which I am pleased to... ► Artikel lesen | |
| 22.08.25 | SenzaGen AB: SenzaGen secures new follow-up order worth approx. 1.0 MSEK for GARD from a global leading U.S. pharmaceutical company | 287 | GlobeNewswire (Europe) | SenzaGen has received a new follow-up order from a global leader in the pharmaceutical and life science industry. The order, valued at approximately 1.0 million SEK, covers testing with GARD®air, SenzaGen's... ► Artikel lesen | |
| 20.08.25 | SenzaGen AB: SenzaGen's interim report January-June 2025 | Strong order intake and expanded OECD approval for GARDskin | 393 | GlobeNewswire (Europe) | Message from the CEO
"We continue to win new customers, and our order intake is significantly higher than our sales for the period, giving us a strong starting position for the coming quarters. Given... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,070 | -0,59 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen nach Zahlen zum zweiten Quartal von 43 auf 47 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Die Resultate... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 12,910 | -3,30 % | Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)'s Cancer Drug Partnership Create a New Treatment Standard? | ||
| APOGEE THERAPEUTICS | 134,53 | -0,02 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| CLIMB BIO | 17,210 | +5,32 % | Climb Bio, Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 387,67 | +5,52 % | Raymond James raises Praxis Precision Medicines price target on pipeline outlook | ||
| VERA THERAPEUTICS | 32,070 | +1,39 % | Goldman Sachs lowers Vera Therapeutics stock price target to $80 | ||
| CG ONCOLOGY | 77,38 | +3,03 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 13,980 | +14,12 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces New Employment Inducement Grants | ||
| ERASCA | 18,680 | +1,58 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 121,13 | +3,20 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| ARCUS BIOSCIENCES | 29,770 | +0,98 % | Arcus Biosciences GAAP EPS of -$0.72 beats by $0.17, revenue of $41M | ||
| COGENT BIOSCIENCES | 37,650 | -0,79 % | Cogent Biosciences, Inc. - 10-Q, Quarterly Report | ||
| IMMUNOME | 27,680 | +1,69 % | Immunome: Varegacestat Cuts Progression Or Death Risk 84% As FDA Decision Targets April 2027 | ||
| EVOTEC | 3,432 | -0,41 % | Evotec Aktie: Lebenszeichen aus der Totenstille - wer kauft denn da? | Die auffällige Ruhe bei der Evotec Aktie, die im letzten 4investors.de-Chartcheck im Mittelpunkt stand, ist durchbrochen. Damals lautete die Frage, ob jemand leise in die Totenstille der Biotechnologie-Aktie... ► Artikel lesen | |
| BIONTECH | 79,25 | -1,55 % | Moderna-Aktie: Plötzlich deutlich besser als BioNTech | Die Moderna-Aktie überrascht die Börse rund um das Wochenende mit einem neuen Höhenflug. Nachdem der Kurs des Biotech-Konzerns bereits am Freitag um +10% in die Höhe geschossen ist, setzt sich die gute... ► Artikel lesen |
SENZAGEN AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,63 % bei einem Aktienkurs von 0,471 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SENZAGEN AB finden Sie auf Wallstreet Online.